FenuLife® Good for Satiety

NORTH BERGEN, N.J.Frutarom released the results of a new satiety and obesity study using its FenuLife® galactomannan ingredient, published in Phytotherapy Research (2009; April 7). The single blind, crossover study tested the effect of 4 g or 8 g of FenuLife galactomannan versus placebo in 18 obese subjects. Following dosage of FenuLife or placebo in a beverage alongside a standardized breakfast, every 30 minutes for 3.5 hours subjects rated their feelings of hunger, satiety, fullness and prospective food consumption using visual analog scales (VAS). Samples of blood for analysis of blood glucose and insulin response also were taken. Subjects were then given an unlimited lunch buffet and recorded food intake for the rest of the day. 

A statistically significant increase (P<0.05) was shown in measurements of satiety and fullness, with reduced ratings of hunger and prospective food consumption at 8 g.  In addition, this dosage showed a trend (P<0.11) toward reduced caloric intake at lunch. The researchers concluded the 8-g dosage may have short-term beneficial effects in obese subjects.

"FenuLife can be an effective ingredient in weight management formulations," says Jocelyn Mathern, R.D., the study's principal investigator and now the Technical Manager for Frutarom Health USA. "Scientific literature points to many benefits of dietary fiber for weight management and this study has shown that FenuLife can have a significant positive effect in increasing feelings of fullness and reducing hunger."